InvestorsHub Logo
Followers 25
Posts 2423
Boards Moderated 0
Alias Born 07/25/2013

Re: None

Thursday, 11/16/2017 8:25:52 AM

Thursday, November 16, 2017 8:25:52 AM

Post# of 345969
Verified November 2017 by Novartis ( Novartis Pharmaceuticals )

They have PS on the table!


Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS


Drug: MBG453
MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).

https://clinicaltrials.gov/ct2/show/NCT03066648
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News